Diagnosis of vertebrogenic pain syndromes
ARTICLE PDF (Українська)


vertebrogen pain syndromes, pain diagnosis, pain management, acute pain, chronic pain

How to Cite

Svyrydova, N., Sereda, V., Dovgiy, I., & Shcherbaty, A. (2018). Diagnosis of vertebrogenic pain syndromes. East European Journal of Neurology, (3(21), 4-12. https://doi.org/10.33444/2411-5797.2018.3(21).4-12


Pain is a condition that is one of the most common diseases in the world. Many patients with vertebrogenic pain syndromes are multimorbidic, so they always receive field pharmacotherapy. Studies on multimorbidity have shown that chronic pain syndromes in the diagnosis and treatment are always interpreted as secondary, associated with somatic and mental disorders. Back pain can be divided into two large groups: vertebrogenic (degenerative, traumatic, inflammatory, neoplastic and other lesions of the vertebrae) and nonvertebrogenic genesis (stretching of ligaments and muscles, myofascial syndromes, fibromyalgia, somatic diseases, psychogenic factors, etc.). further). In the context of discussing vertebrogen pain syndromes, it is necessary to mention degenerative-dystrophic changes (osteochondrosis) of the spine primarily as in the vast majority of cases vertebroneurological pathology is associated with them. The following stages are distinguished: therapeutic, medical-rehabilitation, rehabilitation.

ARTICLE PDF (Українська)


1. Hayden J., Asbridge M., Magee K. (2018) The prevalence of low back pain in the emergency department: a descriptive study set in the Charles V. Keating Emergency and Trauma Centre, Halifax, Nova Scotia, Canada., BMC Musculoskeletal Disorders., 201819:306.
2. World Health Organization. Cancer Pain Relief Geneva:World Health Organization; 1986.
3. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.
4. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.
5. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer. 1987;59(4):850–6.
6. World Health Organization. Cancer pain relief, with a guide to opioid availability. Geneva: WHO; 1996:2nd edition.
7. Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417–33.
8. Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17
9. Pratzel HG1, Alken RG, Ramm S. Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial// Pain. 1996 Oct;67(2-3):417-25.
10. Agarwal S, Patel T, Shah N, Patel B. Comparative study of therapeutic response to baclofen vs tolperisone in spasticity//Biomed Pharmacother. 2017 Mar;87:628-635.
11. Baron R., R. Freynhagen. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy // Pain. — 2010. — Vol. 150, N 3. — P. 420—427.
12. Brevik H. Collet B., Ventetridda V. Survey of chronic pain in Europe : prevalence, impact on daily life and treatment // Eur. J. Pain. — 2006. — Vol. 10. — P. 287—333.
13. Chou R., Qaseem A., Snow V. [et al.]. Diagnosis and Treatment of Low Back Pain : A Joint Clinical Practice Guideline from the American College of Physicians and the American Pain Society // Annals of Internal Medicine. — 2007. — Vol. 147, N 7. — P. 478—491.
14. Мурашко Н.К., Середа В.Г., Пономаренко Ю.В., Довгий І.Л., Парнікоза Т.П., Попов О.В., Пацало Л.М., Терентьєва Н.В., Леснік О.Г. Вертеброгенні больові синдроми: сучасний підхід до лікування (методичні рекомендації)//Методичні рекомендації— 2013, с. 21
15. Muller-Schwefe GH. European survey of chronic pain patients: results for Germany. Curr Med Res Opin. 2011;27(11):2099–106. Epub 2011/09/22.
16. Brochet B, Michel P, Barberger-Gateau P, Dartigues JF. Population-based study of pain in elderly people: a descriptive survey. Age and Ageing. 1998;27(3):279–84.
17. Grimby C, Fastbom J, Forsell Y, Thorslund M, Claesson CB, Winblad B. Musculoskeletal pain and analgesic therapy in a very old population. Arch Gerontol Geriatr. 1999;29(1):29–43.
18. Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA. Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol. 2014;70(5):575–81.
19. Schafer I. Does multimorbidity influence the occurrence rates of chronic conditions? A claims data based comparison of expected and observed prevalence rates. PLoS One. 2012;7(9):e45390
20. van den Bussche H, Schon G, Kolonko T, Hansen H, Wegscheider K, Glaeske G, et al. Patterns of ambulatory medical care utilization in elderly patients with special reference to chronic diseases and multimorbidity—results from a claims data based observational study in Germany. BMC Geriatr. 2011;11(1):54.
21. Gunn JM, Ayton DR, Densley K, Pallant JF, Chondros P, Herrman HE, et al. The association between chronic illness, multimorbidity and depressive symptoms in an Australian primary care cohort. Soc Psychiatry Psychiatr Epidemiol. 2012. Epub 2010/12/25.
22. van Oostrom SH, Picavet HS, van Gelder BM, Lemmens LC, Hoeymans N, van Dijk CE, et al. Multimorbidity and comorbidity in the Dutch population—data from general practices. BMC Public Health. 2012;12(1):715.
23. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 2012;380(9836):37–43.